Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02718859

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

Study of the Combined Therapy of Irreversible Electroporation（IRE） and Nature Killer (NK) Cells for Advanced Pancreatic Cancer

Sponsor: Fuda Cancer Hospital, Guangzhou

Conditions Pancreatic Cancer

Interventions NK cells irreversible electroporation (IRE )

Updated 7 times since 2017 Last updated: Sep 10, 2019 Started: Mar 1, 2016 Primary completion: Mar 1, 2017 Completion: Mar 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Pancreatic Cancer, this trial is completed. The trial is conducted by Fuda Cancer Hospital, Guangzhou and has accumulated 7 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Oct 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed
Jun 2018 — Oct 2019 [monthly]

Unknown Status PHASE1_PHASE2

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2017 — Apr 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Data source: Fuda Cancer Hospital, Guangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China